Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD), a patient-focused biotechnology company specializing in rare diseases, has announced its participation in two major investor conferences in March 2025:
- TD Cowen 45th Annual Health Care Conference in Boston, MA on March 4, 2025, at 9:50 a.m. ET
- Leerink Partners 2025 Global Healthcare Conference in Miami, FL on March 10, 2025, at 10:00 a.m. ET
Both presentations will be accessible via live audio webcast through the investors section of the Amicus Therapeutics corporate website. The company focuses on discovering, developing, and delivering innovative first- or best-in-class medicines for rare disease patients.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FOLD gained 1.77%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.
- TD Cowen 45th Annual Health Care Conference in Boston, MA, on Tuesday, March 4, 2025, at 9:50 a.m. ET
- Leerink Partners 2025 Global Healthcare Conference in Miami, FL, on Monday, March 10, 2025, at 10:00 a.m. ET
A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
When and where will Amicus Therapeutics (FOLD) present at the TD Cowen Healthcare Conference in March 2025?
How can investors access Amicus Therapeutics (FOLD) March 2025 conference presentations?
What is the schedule for FOLD's presentation at the Leerink Partners Conference in March 2025?
What type of medicines does Amicus Therapeutics (FOLD) focus on developing?
